Retatrutide vs 5-Amino-1MQ
Retatrutide and 5-Amino-1MQ both sit in KYIN's Weight Loss / Metabolic category, but they represent almost opposite approaches to metabolic research — a triple hormone-receptor agonist peptide with extensive Phase 3 human trial data, versus a small-molecule enzyme inhibitor that hasn't yet been tested in humans at all.
At a Glance
| Retatrutide | 5-Amino-1MQ | |
|---|---|---|
| Category | Weight Loss / Metabolic | Weight Loss / Metabolic |
| Molecular class | Long-acting, unimolecular triple-receptor agonist peptide | Small-molecule quinolinium compound — not a peptide |
| Discovery | Coskun et al., Cell Metabolism, 2022 (Eli Lilly) | 2018, Watowich & Neelakantan (UT Medical Branch), building on Kraus et al.'s 2014 Nature genetic study |
| Primary mechanism | Simultaneous GIP, GLP-1, and glucagon receptor agonism | Selective NNMT enzyme inhibition |
| Primary research focus | Energy expenditure, glycemic control, body composition | Adipose NAD+/SAM biology, energy expenditure, SIRT1 signaling |
| Human trial data | Phase 2 complete; TRIUMPH-1, -2, -3 (Phase 3) complete or reported | None — all data is preclinical (mouse models) |
| Regulatory status | Investigational; BLA submission planned Q1 2027 | Investigational; no human trials initiated |
| Sold by KYIN | Yes — see product page | Yes — see product page |
How They Differ
Retatrutide came out of Eli Lilly's incretin-biology research group — the same program behind tirzepatide. Where earlier compounds in that line activated one or two hormone receptors, Lilly's researchers engineered Retatrutide as a single molecule that activates three at once: GIP, GLP-1, and glucagon. Adding glucagon receptor activity on top of the two incretin pathways was a deliberate design choice intended to layer glucagon's own energy-expenditure and hepatic lipid-oxidation effects on top of the appetite and glycemic benefits the other two receptors provide. See its full discovery history.
5-Amino-1MQ isn't a peptide at all — it's a small-molecule quinolinium compound, and its research story starts with a gene rather than a drug candidate. A 2014 study led by William Kraus (published in Nature) found that knocking down the enzyme NNMT in obese, diabetic mice raised adipose SAM and NAD+ levels, increased energy expenditure, and protected against diet-induced obesity, establishing NNMT as a promising obesity target. The compound itself followed in 2018, when Stanley Watowich's team at the University of Texas Medical Branch introduced 5-Amino-1MQ as a pharmacological tool to inhibit NNMT directly, rather than knocking out the gene that produces it. See its full discovery history.
Clinical Trial Data
Retatrutide: A Phase 2 trial (New England Journal of Medicine, 2023) reported up to 24.2% mean weight loss at 48 weeks. The Phase 3 TRIUMPH-1 trial (2,339 adults) reported 28.3% mean weight loss at the 12mg dose over 80 weeks, with 45.3% of participants losing at least 30% of body weight. TRIUMPH-2 (published in The Lancet) found 20.8% mean weight loss and up to 1.6% A1C reduction in adults with type 2 diabetes, and TRIUMPH-3 reported 22.6% mean weight loss in adults with cardiovascular disease, though its full results are not yet peer-reviewed. Retatrutide remains investigational and has not received regulatory approval anywhere; Eli Lilly has stated it plans to submit a Biologics License Application to the FDA in Q1 2027.
5-Amino-1MQ: All available data is preclinical. The 2014 genetic knockdown study (Kraus et al., Nature) established NNMT as an obesity-relevant target in mice, and the 2018 pharmacology study (Neelakantan et al., Biochemical Pharmacology) introduced 5-Amino-1MQ itself, showing it reduced body weight and white adipose mass in diet-induced obese mice without affecting food intake or lean mass. No human clinical trials of 5-Amino-1MQ have been conducted.
Why They're Both in the Weight Loss / Metabolic Category
Retatrutide and 5-Amino-1MQ aren't studied as a combination — they work through unrelated mechanisms and sit at very different stages of the research pipeline. The comparison is useful precisely because of that contrast: Retatrutide illustrates how far receptor-agonist pharmacology has advanced in this category, with multiple completed Phase 3 trials and a near-term regulatory filing, while 5-Amino-1MQ illustrates an earlier-stage, mechanistically distinct approach — enzyme inhibition rather than receptor engagement — that remains entirely in the preclinical, animal-model stage. Together they show the range of mechanisms researchers are exploring under the broader umbrella of metabolic and weight-related research.
Retatrutide vs 5-Amino-1MQ questions
What is the main difference between Retatrutide and 5-Amino-1MQ?
Retatrutide is a peptide that activates the GIP, GLP-1, and glucagon receptors simultaneously. 5-Amino-1MQ is not a peptide at all — it's a small-molecule quinolinium compound that works by inhibiting the enzyme NNMT. Both are studied in weight-loss and metabolic research, but through completely different mechanisms: receptor agonism versus enzyme inhibition.
Which has more human clinical trial data, Retatrutide or 5-Amino-1MQ?
Retatrutide, by a wide margin. It has completed Phase 2 and three Phase 3 trials (TRIUMPH-1 through TRIUMPH-3) involving thousands of participants. No human clinical trials of 5-Amino-1MQ have been conducted — all available data comes from a 2014 genetic knockdown study and a 2018 pharmacology study, both in mice.
Does this comparison mean Retatrutide and 5-Amino-1MQ are approved for a particular use?
No. Retatrutide remains investigational and has not received regulatory approval anywhere. 5-Amino-1MQ has no human trial data of any kind. This page compares both for educational and research context only; KYIN Peptides sells both strictly for laboratory research use, not for human or animal use.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.